Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine + epirubicin vs epirubicin + docetaxel in first-line treatment of advanced breast cancer
2004-003786-33Phase 2Active
- Sponsor
- Gruppo Oncologico del Nord
- Start
- Jul 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing vinorelbine + epirubicin with epirubicin + docetaxel (2 arms). Primary endpoints: Time to progression of disease, Objective response rate and 1 more. Started Jul 2005; status: active.
02
Drugs
vinorelbineepirubicindocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-003786-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003786-33.